与英格兰的BA.2病例相比，SARS-CoV-2奥密克戎BA.4和BA.5病例出现严重后果的风险。 - Suppr

Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England.

作者信息

Abdul Aziz Nurin, Nash Sophie Grace, Zaidi Asad, Nyberg Tommy, Groves Natalie, Hope Russell, Lopez Bernal Jamie, Dabrera Gavin, Thelwall Simon

机构信息

UKHSA COVID-19 Vaccines and Epidemiology Division, UK.

出版信息

J Infect. 2023 Jul;87(1):e8-e11. doi: 10.1016/j.jinf.2023.04.015. Epub 2023 Apr 24.

DOI:10.1016/j.jinf.2023.04.015

PMID:37100176

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10124096/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04d3/10124096/2879817ecce9/gr1_lrg.jpg

相似文献

Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England.

J Infect. 2023 Jul;87(1):e8-e11. doi: 10.1016/j.jinf.2023.04.015. Epub 2023 Apr 24.

Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.

Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.

JAMA Netw Open. 2022 Oct 3;5(10):e2238354. doi: 10.1001/jamanetworkopen.2022.38354.

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England.

Influenza Other Respir Viruses. 2023 May;17(5):e13150. doi: 10.1111/irv.13150.

Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England.

Nat Commun. 2022 Oct 13;13(1):6053. doi: 10.1038/s41467-022-33740-9.

Dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022 in England.

Nat Commun. 2022 Aug 3;13(1):4500. doi: 10.1038/s41467-022-32121-6.

Twin peaks: The Omicron SARS-CoV-2 BA.1 and BA.2 epidemics in England.

Science. 2022 Jun 24;376(6600):eabq4411. doi: 10.1126/science.abq4411.

Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2.

Epidemiol Infect. 2022 Dec 20;151:e32. doi: 10.1017/S0950268822001935.

Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort.

JAMA Netw Open. 2024 Aug 1;7(8):e2430983. doi: 10.1001/jamanetworkopen.2024.30983.

Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.

Vaccine. 2023 Mar 24;41(13):2280-2288. doi: 10.1016/j.vaccine.2023.02.062. Epub 2023 Feb 27.

引用本文的文献

Correlation of severity & clinical outcomes of COVID-19 with virus variants: A prospective, multicentre hospital network study.

Indian J Med Res. 2024 Jan 1;159(1):91-101. doi: 10.4103/ijmr.ijmr_1041_23. Epub 2024 Mar 4.

Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England.

Lancet Reg Health Eur. 2023 Oct 26;35:100755. doi: 10.1016/j.lanepe.2023.100755. eCollection 2023 Dec.

Risk of severe outcomes among Omicron sub-lineages BA.4.6, BA.2.75, and BQ.1 compared to BA.5 in England.

Epidemiol Infect. 2023 Oct 31;151:e189. doi: 10.1017/S0950268823001760.

An ARMS-Multiplex PCR Targeting SARS-CoV-2 Omicron Sub-Variants.

Pathogens. 2023 Aug 6;12(8):1017. doi: 10.3390/pathogens12081017.

本文引用的文献

Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study.

J Infect. 2023 May;86(5):e148-e151. doi: 10.1016/j.jinf.2023.01.015. Epub 2023 Jan 18.

Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.

Int J Infect Dis. 2023 Feb;127:63-68. doi: 10.1016/j.ijid.2022.11.024. Epub 2022 Nov 24.

Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.

Lancet Infect Dis. 2023 Feb;23(2):167-176. doi: 10.1016/S1473-3099(22)00595-3. Epub 2022 Oct 18.

Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England.

Nat Commun. 2022 Oct 13;13(1):6053. doi: 10.1038/s41467-022-33740-9.

Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa.

Nat Commun. 2022 Oct 4;13(1):5860. doi: 10.1038/s41467-022-33614-0.

Variation in reported SARS-CoV-2 cases after testing policy changes.

Lancet Infect Dis. 2022 Oct;22(10):1418-1419. doi: 10.1016/S1473-3099(22)00572-2. Epub 2022 Aug 23.

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.

Nature. 2022 Aug;608(7923):603-608. doi: 10.1038/s41586-022-05053-w. Epub 2022 Jul 5.

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.

Lancet. 2022 Apr 2;399(10332):1303-1312. doi: 10.1016/S0140-6736(22)00462-7. Epub 2022 Mar 16.

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.

Lancet Respir Med. 2020 May;8(5):506-517. doi: 10.1016/S2213-2600(20)30161-2. Epub 2020 Apr 6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献